Clinical Trial Update: Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-12-02